TFF2

Across TCGA pan-cancer cohorts, TFF2 RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated TFF2 data layer compared with 1 for mutation status and 2 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TFF2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated TFF2 expression acts as an unfavorable survival marker, although some lineages such as UCS and BLCA show a favorable association.

LIHC, ESCA, and KICH are the cancer types where TFF2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.411	0.653	<.001	63	view →
ESCA	DFS	Median	All	0.405	1.000	<.001	30	view →
KICH	OS	Tertile	III,IV	0.228	0.860	<.001	29	view →
UCS	OS	Quartile	III,IV	0.730	0.360	.008	24	view →
ACC	DFS	Tertile	IV	0.067	0.402	.025	18	view →
BLCA	OS	Quartile	II,III,IV	0.706	0.507	.002	17	view →
KIRC	DFS	Tertile	All	0.513	0.705	.002	13	view →
MESO	OS	Median	All	0.439	0.603	.022	13	view →
SKCM	OS	Median	IV	0.765	0.316	.010	12	view →
SCLC	DFS	Quartile	IV	0.110	0.542	.008	12	view →
PCPG	DFS	Tertile	All	0.848	0.946	.045	12	view →
CHOL	OS	Median	All	0.312	0.876	<.001	11	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 18 lineages.

TFF2–LIHC (OS)

Open the LIHC breakdown →